06.19.2023 - By PeerVoice
Visit https://www.peervoice.com/XPV860 to view the entire programme with slides. After completing “Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk”, participants will be able to: Across clinical studies of HER2-targeted therapies for HER2-positive breast cancer, assess the incidence rates of drug-induced interstitial lung disease (ILD); Formulate practical approaches to optimise the monitoring for drug-induced ILD in patients with HER2-positive breast cancer; and Use effective, evidence-based strategies for managing drug-induced ILD in patients with HER2-positive breast cancer.